Remarkable Growth for Firefly Neuroscience in Q3 2025
Firefly Neuroscience, Inc. (“Firefly”) (NASDAQ: AIFF), an innovative leader in artificial intelligence focused on improving brain health, has released its financial results for the third quarter of 2025. The company’s efforts to better serve patients with neurological and mental disorders are beginning to bear fruit, as evidenced by robust revenue growth and a leaner cost structure.
Significant Business Highlights
In this quarter, Firefly achieved a remarkable more-than-tenfold increase in revenue compared to the previous year, showcasing not only the benefits of the strategic acquisition of Evoke Neuroscience but also the effectiveness of the two companies’ integration.
Steady Quarter-over-Quarter Success
The EEG/ERP scan volumes rose by 10.9% sequentially, indicating the company’s growing influence in the neuroscience space. Furthermore, operating expenses saw a significant decrease of 35%, leading to a reduced net loss of $2.6 million, compared to $4.3 million the previous year. Such financial improvements underscore Firefly’s commitment to enhancing efficiency and operational performance.
Innovative Collaborations and Developments
Firefly has also been collaborating with leaders in the field, including Prof. Dr. med. Christian Schaaf on ground-breaking studies in human genetics, which will potentially open new avenues in understanding brain health.
Introduction of the CLEAR Platform
In August, Firefly unveiled the ‘CLEAR’ platform aimed at improving EEG data quality. This new technology represents a huge advancement in how the company processes and analyzes brain data, relying on NVIDIA's cutting-edge hardware to enhance its capabilities.
Expanding Reach in Cognitive Electrophysiology
Furthermore, the partnership with HealingMaps aims to provide cognitive electrophysiology analytics across thousands of clinics. This strategic initiative illustrates Firefly's goal to broaden its accessibility and impact across North America, tapping into the potential of therapies like ketamine and psilocybin.
Financial Overview: Q3 2025 Results
For the quarter ending September 30, 2025, Firefly reported revenues of $388,000, significantly increased from $33,000 during the same period the previous year. This growth reinforces the value of the company’s integration strategy with Evoke Neuroscience.
Dramatic Decrease in Operating Expenses
Operating expenses in the third quarter fell to about $2.8 million, a decrease from the prior year’s $4.3 million. This reduction was driven by rationalizing various costs related to equity vesting and consulting fees from rebranding efforts.
Cash Flow and Financial Health
During this quarter, cash usage in operations has significantly declined to roughly $1.5 million, the lowest for the first three quarters of 2025. By the end of Q3, the company reported $4.3 million in cash reserves, indicating a solid financial foundation to support its growth initiatives.
About Firefly Neuroscience
Firefly Neuroscience (NASDAQ: AIFF) aims to provide top-tier insights into brain functionality through its vast database of over 191,000 EEG and ERP brain scans. As the world's largest standardized EEG/ERP repository, Firefly continues to innovate, with the potential to revolutionize diagnostics for various neurological conditions.
For further information, reach out to Stephen Kilmer at (646) 274-3580 or via email at stephen.kilmer@fireflyneuro.com.
Frequently Asked Questions
What were Firefly's revenues for Q3 2025?
Firefly reported revenues of $388,000 for the third quarter of 2025.
How much did Firefly’s operating expenses decrease?
Operating expenses decreased by 35%, down to approximately $2.8 million.
What is the CLEAR platform introduced by Firefly?
The CLEAR platform is a new technology designed to enhance EEG data quality for improved analysis.
Who is Firefly collaborating with on genetic studies?
Firefly is collaborating with Prof. Dr. med. Christian Schaaf on research regarding neurophysiological impacts related to genetics.
How has Firefly planned to expand its reach?
Firefly partnered with HealingMaps to provide analytics for cognitive electrophysiology to over 2,500 clinics across North America.
